NCT07431840 Immune Defense Protein Impact On Respiratory Immune Outcomes
| NCT ID | NCT07431840 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Quantec Ltd |
| Condition | Upper Respiratory Disease |
| Study Type | INTERVENTIONAL |
| Enrollment | 300 participants |
| Start Date | 2025-12-05 |
| Primary Completion | 2026-05-19 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 300 participants in total. It began in 2025-12-05 with a primary completion date of 2026-05-19.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The primary goal of this study is to observe the impact of the IDP® Supplement on the duration and severity of upper respiratory symptoms in older individuals during the cold and flu season. Secondary aims include observing the product's effect on rescue medication use, quality of life, and overall tolerability. This is conducted as a consumer-driven, decentralized observational clinical research study in adults aged 60 or older, using self-reported measures and questionnaires completed at home via the Chloe App.
Eligibility Criteria
Inclusion Criteria: 1. Age 60 years and older 2. Individuals who experience upper respiratory symptoms (e.g. coughing, sneezing, congestion) at least 2-3 times during the cold/flu season. 3. Able to read and understand English. 4. Able to read, understand, and provide informed consent. 5. Able to use a personal smartphone device and download Chloe by People Science. 6. Able to receive shipment of the product at an address within the United States. Exclusion Criteria: Any potential participants who: 1. Do not have a personal smartphone, internet access, or unwilling to download Chloe. 2. Already in an immunocompromised state, including: A. Infectious Causes * HIV/AIDS * Chronic hepatitis B or C (advanced stages) * Tuberculosis (especially disseminated or extrapulmonary TB) B. Cancer-Related * Leukemia (e.g., AML, ALL, CLL) * Lymphoma (e.g., Hodgkin's and Non-Hodgkin's) * Multiple Myeloma * Any metastatic cancer receiving chemotherapy C. Immunosuppressive Therapy: Participants on: * Corticosteroids (e.g., ≥20 mg/day of prednisone for ≥2 weeks) * Biologics (e.g., TNF inhibitors like infliximab, adalimumab) * Calcineurin inhibitors (e.g., tacrolimus, cyclosporine) * mTOR inhibitors (e.g., sirolimus) * JAK inhibitors (e.g., tofacitinib) * Chemotherapy or radiation therapy * Anti-rejection meds post-organ transplant D. Transplant Patients * Solid organ transplant (kidney, liver, heart, lung) * Hematopoietic stem cell transplant (HSCT) E. Autoimmune or Inflammatory Diseases (especially when treated with immunosuppressants) * Rheumatoid Arthritis * Systemic Lupus Erythematosus (SLE) * Psoriasis or Psoriatic Arthritis * Inflammatory Bowel Disease (Crohn's disease, Ulcerative colitis) * Multiple Sclerosis (especially on disease-modifying therapies) 3. Other Concomitant Conditions and Therapies: 1. Any investigational therapies or treatments within 30 days prior to enrollment. 2. Known diagnosis of Asthma and/or COPD 3. Currently diagnosed with Alcohol Use Disorder and/or Substance Use Disorder 4. Any underlying medical conditions or comorbidities that may confound the evaluation of the study outcomes 5. Have a significant illness, disease or condition which, in the opinion of the principal investigator, may impact their ability to participate in the study or impact the study outcomes 4. Use of cannabis-containing products daily 5. Use of nicotine-containing products daily 6. Known hypersensitivity or previous allergic reaction to milk products, Sorbitol and/or tabletting aids. 7. Are unlikely for any reason to be able to comply with the trial or considered unsuited for participation in the study by the Principal Investigator.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07431840 clinical trial?
This trial is open to participants of all sexes, aged 60 Years or older, studying Upper Respiratory Disease. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07431840 currently recruiting?
Yes, NCT07431840 is actively recruiting participants. Contact the research team at noah@peoplescience.health for enrollment information.
Where is the NCT07431840 trial being conducted?
This trial is being conducted at Los Angeles, United States.
Who is sponsoring the NCT07431840 clinical trial?
NCT07431840 is sponsored by Quantec Ltd. The trial plans to enroll 300 participants.